×
About 983 results

ALLMedicine™ Eosinophilic Granulomatosis With Polyangiitis Center

Research & Reviews  355 results

Cutaneous manifestations of ANCA-associated vasculitis: a retrospective review of 211 c...
https://doi.org/10.1111/ijd.16214
International Journal of Dermatology; Shakshouk H, Gibson LE

May 17th, 2022 - ANCA-associated vasculitis (AAV) may present a wide array of dermatological manifestations. Patients may remain ANCA negative, rendering diagnosis challenging for dermatologists if they depend heavily on ANCA testing to either confirm or rule out ...

Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
https://clinicaltrials.gov/ct2/show/NCT00315380

May 17th, 2022 - EGPA, also known as allergic granulomatosis angiitis, is a systemic vasculitis. EGPA is marked by three distinct symptoms: asthma; eosinophilia, evidenced by an excessive number of eosinophils in the blood and tissues; and vasculitis involving the...

Added value of Joint ENT-Rheumatology clinic in the management of ANCA-associated vascu...
https://doi.org/10.1016/j.amjoto.2022.103485
American Journal of Otolaryngology; Stavrakas M, Smith R et. al.

May 15th, 2022 - ANCA-associated vasculitides (AAV) represent a group of diagnoses, including granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) and microscopic polyangiitis (MPA). Most commonly, they present initially wit...

Successful benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis wit...
https://doi.org/10.55563/clinexprheumatol/ahyqld
Clinical and Experimental Rheumatology; Belfeki N, Abroug S et. al.

May 7th, 2022 - Eosinophilic granulomatosis with polyangiitis (EGPA) is characterised by many features, including asthma, allergic rhinitis, peripheral and tissue eosinophilia, and vasculitis. Its pathophysiology is still unclear and we suggest that there are dif...

Recrudescence of severe polyneuropathy after receiving Pfizer-BioNTech COVID-19 vaccine...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058677
BMJ Case Reports; Gill R, Rizvi M et. al.

Apr 30th, 2022 - A middle age man with a history of diabetes mellitus type 2, hypertension, migraine and eosinophilic granulomatosis with polyangiitis (EGPA) with polyneuropathy in remission presented with paresthesia and motor weakness soon after receiving the Pf...

see more →

Guidelines  2 results

2022 American College of Rheumatology/European Alliance of Associations for Rheumatolog...
https://doi.org/10.1002/art.41982
Arthritis & Rheumatology (Hoboken, N.J.); Grayson PC, Ponte C et. al.

Feb 3rd, 2022 - To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA). Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) iden...

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Managemen...
https://doi.org/10.1002/art.41773
Arthritis & Rheumatology (Hoboken, N.J.); Chung SA, Langford CA et. al.

Jul 9th, 2021 - To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  9 results

Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
https://clinicaltrials.gov/ct2/show/NCT00315380

May 17th, 2022 - EGPA, also known as allergic granulomatosis angiitis, is a systemic vasculitis. EGPA is marked by three distinct symptoms: asthma; eosinophilia, evidenced by an excessive number of eosinophils in the blood and tissues; and vasculitis involving the...

Hydroxychloroquine in ANCA Vasculitis Evaluation
https://clinicaltrials.gov/ct2/show/NCT04316494

Mar 18th, 2022 - This is a multi-centre, randomised, placebo-controlled, double-blind study to evaluate if hydroxychloroquine in combination with background maintenance therapy improves the clinical response and quality of life in patients with AAV. 76 participant...

Analgesic Effect of rTMS in Vasculitic Neuropathy
https://clinicaltrials.gov/ct2/show/NCT04720196

Mar 8th, 2022 - Vasculitic neuropathies (VN) are a group of disorders resulting from inflammation of predominantly small vessels with destruction of their walls and subsequent ischemic damage of peripheral nerves. Neural damage may or may not coexist with the dam...

Rituximab in Eosinophilic Granulomatosis With Polyangiitis
https://clinicaltrials.gov/ct2/show/NCT02807103

Apr 14th, 2021 - Systemic vasculitides are inflammatory diseases of blood vessels, among which anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are often severe with life-threatening manifestations or complications. AAV include granulomato...

Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease
https://clinicaltrials.gov/ct2/show/NCT03455686

Sep 3rd, 2020 - The primary objective of this study is to evaluate the ventilation defect percent (VDP), apparent diffusion coefficient (ADC) and/or the signal-to-noise ratio (SNR) obtained by analysis of hyperpolarized 129Xe MRI at one or more time-points (over ...

see more →

News  22 results

Rituximab, Cyclophosphamide Similar for Inducing EGPA Remission
https://www.medscape.com/viewarticle/963134

Nov 17th, 2021 - Rituximab didn't perform any worse or better at inducing remission after a year in patients with eosinophilic granulomatosis with polyangiitis (EGPA) than did conventional treatment with cyclophosphamide in the phase 3 REOVAS trial conducted in Fr...

New ACR Guidelines Give Advice on Six Forms of Vasculitis
https://www.medscape.com/viewarticle/954873

Jul 15th, 2021 - Three new guidelines from the American College of Rheumatology, in partnership with the Vasculitis Foundation, offer evidence-based recommendations for managing and treating six different forms of systemic vasculitis. Dr Sharon Chung "It's not unu...

FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome
https://www.staging.medscape.com/viewarticle/938221

Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

CellCept Succeeds in ANCA Vasculitis
https://www.medpagetoday.com/rheumatology/generalrheumatology/86348

May 7th, 2020 - Mycophenolate mofetil (CellCept) was as effective as cyclophosphamide for remission induction in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, Japanese researchers reported. In a meta-analysis of four clinical trials, the overa...

FDA OKs Mepolizumab (Nucala) for Younger Children With Severe Asthma
https://www.medscape.com/viewarticle/918328

Sep 12th, 2019 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to children as young as 6 years old with severe eosinophilic asthma. Mepolizumab subcutaneous injection was first approved in the Unite...

see more →

Patient Education  4 results see all →